PRPF8

Across TCGA pan-cancer cohorts, PRPF8 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PRPF8 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PRPF8 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRPF8 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where PRPF8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.234	0.895	<.001	61	view →
LUAD	DFS	Quartile	All	0.978	0.820	.007	27	view →
CCRCC	DFS	Median	All	0.678	0.913	<.001	26	view →
LSCC	OS	Tertile	All	0.907	0.700	.015	14	view →
UCEC	DFS	Tertile	All	0.828	0.945	.040	6	view →
PDAC	DFS	Quartile	II,III,IV	0.322	0.579	.018	2	view →
GBM	OS	Tertile	All	0.547	0.364	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PRPF8–HNSC (DFS)

Open the HNSC breakdown →